mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
التاريخ
2021-09-01المؤلف
Chemaitelly, HiamYassine, Hadi M.
Benslimane, Fatiha M.
Al Khatib, Hebah A.
Tang, Patrick
Hasan, Mohammad R.
Malek, Joel A.
Coyle, Peter
Ayoub, Houssein H.
Al Kanaani, Zaina
Al Kuwari, Einas
Jeremijenko, Andrew
Kaleeckal, Anvar Hassan
Latif, Ali Nizar
Shaik, Riyazuddin Mohammad
Abdul Rahim, Hanan F.
Nasrallah, Gheyath K.
Al Kuwari, Mohamed Ghaith
Al Romaihi, Hamad Eid
Al-Thani, Mohamed H.
Al Khal, Abdullatif
Butt, Adeel A.
Bertollini, Roberto
Abu-Raddad, Laith J.
...show more authors ...show less authors
البيانات الوصفية
عرض كامل للتسجيلةالملخص
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7–91.5%) ≥14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8–100.0%) ≥14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5–65.5%) and 96.4% after the second dose (95% CI: 91.9–98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0–88.8%) and 95.7% (95% CI: 73.4–99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose.
معرّف المصادر الموحد
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85110038106&origin=inwardالمجموعات
- الأبحاث [709 items ]
- العلوم الحيوية الطبية [692 items ]
- أبحاث فيروس كورونا المستجد (كوفيد-19) [798 items ]
- الرياضيات والإحصاء والفيزياء [717 items ]
- الصحة العامة [401 items ]